Russell Cohen to Gastrointestinal Agents
This is a "connection" page, showing publications Russell Cohen has written about Gastrointestinal Agents.
Connection Strength
2.877
-
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis. 2020 Feb 10; 14(2):192-204.
Score: 0.549
-
Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007 Nov; 62(11):1013-4.
Score: 0.235
-
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center. Dig Dis Sci. 2025 May; 70(5):1864-1872.
Score: 0.195
-
Infliximab in ulcerative colitis: is there a placebo (effect) in the house? Gastroenterology. 2003 Jun; 124(7):1990-1; discussion 1991.
Score: 0.173
-
Infliximab as first-line therapy for severe Crohn's disease? Inflamm Bowel Dis. 2002 Jan; 8(1):58-9; discussion 63-5.
Score: 0.157
-
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S17-22.
Score: 0.150
-
Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77.
Score: 0.145
-
Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
Score: 0.134
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.132
-
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688.
Score: 0.123
-
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
Score: 0.123
-
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
Score: 0.122
-
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
Score: 0.120
-
The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 06; 61(6):1622-7.
Score: 0.103
-
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23.
Score: 0.090
-
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22.
Score: 0.082
-
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8.
Score: 0.049
-
Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005 Jan 06; 57(2):281-302.
Score: 0.048
-
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
Score: 0.045
-
Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2002 Dec; 4(6):497-505.
Score: 0.042
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.035
-
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
Score: 0.013
-
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30.
Score: 0.013